Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs Marriott International Inc (MAR) Price & Performance

Davita IncTrade
Marriott International Inc Trade

Price performance (Past 24H)

Key statistics

Davita Inc vs Marriott International Inc — how do they compare? Davita Inc trades at $179.12 (market cap $11.29B), while Marriott International Inc trades at $363.73 (market cap $94.16B). The key difference: Marriott International Inc is far larger — about 8.3× Davita Inc's market cap, and Marriott International Inc pays a 0.81% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Marriott International Inc for 164 Days on average.

DVAMAR
Market Cap
$11.29B$94.16B
Volume
582,204996,176
Sector
HealthConsumer Cyclical
52-Week High
$240.96$402.54
52-Week Low
$103.87$259.04
Typical Hold Time
114 Days164 Days
Enterprise Value
$24.01B$111.47B
Dividend Yield
—0.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $179.02, up 1.26% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 6.05% net margins and 635% ROE. Recent partnerships with Humana expand value-based kidney care services, while institutional investors like BlackRock added significant positions. Revenue growth remains steady at $13.6B annually with improving profitability trends.

DVA presents a mixed outlook with strong operational performance offset by technical weakness. The 43% upside to consensus price target of $235.67 offers potential, but high debt levels and regulatory risks require monitoring. Recent earnings momentum and expanding Medicare partnerships support long-term growth, though current technical indicators suggest near-term consolidation.

Marriott International Inc

Marriott International (MAR) trades at $363.49, up 1.96% today, showing strong momentum near resistance at $364. The stock maintains a bullish technical outlook with positive moving averages and ADX signals. Fundamentally, revenue grew to $26.19B in 2025 with a 9.62% net margin, though valuation metrics appear elevated with a P/E of 37.38. Recent earnings beat expectations in Q1 and Q2 2026, while analysts maintain a consensus price target of $386.71 with 44% buy ratings.

Outlook remains positive driven by travel demand recovery and strategic partnerships, but risks include rising debt levels (debt-to-asset ratio at 58.83% in 2025) and economic sensitivity. The stock offers moderate upside to analyst targets with institutional confidence, though high valuation requires sustained earnings growth to justify current levels.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DVA
100% Buy0% Sell
Avg holding period · 114 Days
MAR
21% Buy79% Sell
Avg holding period · 164 Days

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA →

About Marriott International Inc

Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.

Read more on MAR →